All In Biotech

Drug Trial Radar · NCT07610005

A Relative Bioavailability and Bioequivalence Study of Varegacestat in Healthy Participants

A Phase 1, Open-Label, Crossover Study to Assess the Relative Bioavailability and Bioequivalence of Varegacestat Administered in Different Dose Forms in Healthy Participants

Last checked: Nov 20, 2026Latest source record: Oct 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

44

Planned (sponsor's estimate)

Start

May 21, 2026

Primary completion

May 2027

Study completion May 2027

Sponsor

Lead sponsor
Immunome, Inc.Industry
Sponsor type
Industry
First posted
May 27, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Other
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is an open-label, randomized, crossover study to evaluate the relative bioavailability (rBA) and bioequivalence (BE) of a test capsule formulation of varegacestat compared to reference capsules formulation under fasting conditions.

Conditions

  • Healthy

Interventions

  • Varegacestat Reference FormulationDrug

    Oral administration

  • Varegacestat Test Formulation ADrug

    Oral administration

  • Varegacestat Test Formulation BDrug

    Oral administration

  • Varegacestat Test Formulation CDrug

    Oral administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Evaluate the rBA of varegacestat by AUC0-tTime frame: Approximately 3 weeks
  2. Evaluate the rBA of varegacestat by AUC0-infTime frame: Approximately 3 weeks
  3. Evaluate the rBA of varegacestat by CmaxTime frame: Approximately 3 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Celerion, Inc.

    Tempe, Arizona · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.